These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 20859245)

  • 1. Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol.
    Giegling I; Drago A; Dolžan V; Plesničar BK; Schäfer M; Hartmann AM; Sander T; Toliat MR; Möller HJ; Stassen HH; Rujescu D; Serretti A
    Pharmacogenet Genomics; 2011 Apr; 21(4):206-16. PubMed ID: 20859245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
    Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
    Zivković M; Mihaljević-Peles A; Sagud M; Silić A; Mihanović M
    Psychiatr Danub; 2010 Mar; 22(1):112-6. PubMed ID: 20305604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased plasma glutamate by antipsychotic medication and its relationship to glutaminase 1 and 2 genotypes in schizophrenia -- Juntendo University Schizophrenia Projects (JUSP).
    Maeshima H; Ohnuma T; Sakai Y; Shibata N; Baba H; Ihara H; Higashi M; Ohkubo T; Nozawa E; Abe S; Ichikawa A; Nakano Y; Utsumi Y; Suzuki T; Arai H
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1410-8. PubMed ID: 17669570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of 2-(4-ethyl-1-piperazinyl)-4-(fluorophenyl)-5,6,7,8,9, 10-hexahydrocycloocta[b]pyridine (AD-5423) and haloperidol for their pharmacological activities related to antipsychotic efficacy and/or adverse side-effects.
    Noda Y; Kurumiya S; Miura Y; Oka M
    J Pharmacol Exp Ther; 1993 May; 265(2):745-51. PubMed ID: 8098763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol.
    Corripio I; Catafau AM; Perez V; Puigdemont D; Mena E; Aguilar Y; Carrió I; Alvarez E
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):91-6. PubMed ID: 15610950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
    Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible biomarkers modulating haloperidol efficacy and/or tolerability.
    Porcelli S; Crisafulli C; Calabrò M; Serretti A; Rujescu D
    Pharmacogenomics; 2016 Apr; 17(5):507-29. PubMed ID: 27023437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia.
    Souza RP; Remington G; Meltzer HY; Lieberman JA; Kennedy JL; Wong AH
    Int Clin Psychopharmacol; 2010 Sep; 25(5):264-9. PubMed ID: 20436352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open, randomized, comparative study of efficacy and safety of risperidone and haloperidol in schizophrenia.
    Tamrakar SM; Nepal MK; Koirala NR; Sharma VD; Gurung CK; Adhikari SR
    Kathmandu Univ Med J (KUMJ); 2006; 4(2):152-60. PubMed ID: 18603890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia.
    Banerjee SP; Zuck LG; Yablonsky-Alter E; Lidsky TI
    Neuroreport; 1995 Dec; 6(18):2500-4. PubMed ID: 8741750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Deterioration of schizoaffective disorder due to an interaction between haloperidol and carbamazepine].
    Schalekamp T
    Ned Tijdschr Geneeskd; 2003 Feb; 147(8):365; author reply 365. PubMed ID: 12661128
    [No Abstract]   [Full Text] [Related]  

  • 14. [Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind study].
    Fleischhacker WW; Barnas C; Stuppäck CH; Sperner-Unterweger B; Miller C; Hinterhuber H
    Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():10-3. PubMed ID: 1683332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Causes of haloperidol discontinuation in patients with Tourette's disorder: management and alternatives.
    Silva RR; Muñoz DM; Daniel W; Barickman J; Friedhoff AJ
    J Clin Psychiatry; 1996 Mar; 57(3):129-35. PubMed ID: 8617698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study.
    Sivrioglu EY; Kirli S; Sipahioglu D; Gursoy B; Sarandöl E
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1493-9. PubMed ID: 17688987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of
    Parkhomenko AA; Zastrozhin MS; Skryabin V; Petukhov AE; Pozdniakov SA; Ivanchenko VA; Zaytsev IA; Bure IV; Bochkov PO; Akmalova KA; Smirnov VV; Bryun EA; Sychev DA
    Psychopharmacol Bull; 2023 Dec; 53(4):8-14. PubMed ID: 38076668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
    Kane JM; Lauriello J; Laska E; Di Marino M; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S29-35. PubMed ID: 18334910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary retention with venlafaxine-haloperidol combination.
    Benazzi F
    Pharmacopsychiatry; 1997 Jan; 30(1):27. PubMed ID: 9065967
    [No Abstract]   [Full Text] [Related]  

  • 20. Amoxapine as an antipsychotic: comparative study versus haloperidol.
    Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
    J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.